- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04651790
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)
October 20, 2022 updated by: Pontificia Universidad Catolica de Chile
Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.
The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults.
Two doses of the vaccine will be administered in a 0,14 and a 0,28-day schedule.
Follow-up of safety and efficacy will be assessed for 12 months after the first dose.
Immunogenicity will be studied in a subgroup of participants.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults.
This study will be performed in 8 centers.
Two schedules will be compared: 0,14 and 0,28-day, at a 1:1 rate.
40% of participants will be 60 or more years-old.
Follow-up of safety and efficacy will be assessed for 12 months after administering the first dose.
The collection of the data will be through an electronic Case Report Form.
Immunogenicity will be studied in a subgroup of participants.
Initially, 2,300 volunteers will be recruited.
Study Type
Interventional
Enrollment (Actual)
2300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RM
-
Santiago, RM, Chile, 7770228
- Centro de Especialidades Médicas, Red de Salud UC Christus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults over 18 years of age.
- Demonstrate the capacity to understand and sign the Informed Consent document.
- Agree to comply with the study procedures and visits.
Exclusion Criteria:
- History of confirmed symptomatic SARS CoV-2 infection.
- Pregnant (confirmed by positive urine pregnancy test) or breastfeeding females, and/or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination.
- History of an allergic reaction to the vaccine or components of the study vaccine or placebo.
- Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic, or renal disease, according to anamnesis or physical examination; Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease.
- Diseases that impair the immune system including neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies, and uncontrolled autoimmune diseases not controlled according to anamnesis or physical examination.
- Behavioral, cognitive, or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol.
- Use of immunosuppressive therapies six months before inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
- Have received an immunosuppressive dose of corticosteroids in the last three months before inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg/day for adults for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive.
- History of asplenia, either anatomic or functional.
- History of bleeding disorders, as deficiency of clotting factors, coagulopathy, platelet dysfunction, or previous history of bleeding or significant bruising after IM injection or venipuncture.
- Any alcohol or drug abuse in the last 12 months before inclusion in the study that has caused medical, professional, or family problems, as indicated by clinical history.
- Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study.
- Have received any vaccine with a live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days before their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study.
- Participation in another clinical trial with product administration under investigation during the six months before its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion.
- Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine.
- Fever (>37.8°C) within 72 hours before vaccination.
- Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vaccine 0-14
Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
|
The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Other Names:
|
Experimental: Vaccine 0-28
Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
|
The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of solicited and unsolicited adverse events that occur during the period of one week after each dose of the vaccine in two vaccination schedules: 0,14 and 0,28 days stratified by age group (18-59 years, and 60 or more years).
Time Frame: During the first 7 days after each dose of vaccine
|
The frequency of solicited and unsolicited local and systemic adverse reactions will be registered.
This will be measured during the first 7 days after each vaccination.
These adverse reactions will be registered according to the age group in adults (18-59 years old) and the elderly (60 years of age or older).
|
During the first 7 days after each dose of vaccine
|
Incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule.
Time Frame: Two weeks after second dose up to one year after first dose
|
Vaccine efficacy to prevent virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule will be determined
|
Two weeks after second dose up to one year after first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules
Time Frame: Since two weeks after the second dose of two vaccination schedules and up 12 month after first dose
|
The incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules will be determined.
|
Since two weeks after the second dose of two vaccination schedules and up 12 month after first dose
|
Incidence of severe cases or deaths of COVID-19 virologically confirmed two weeks after the second vaccination of two vaccination schedules
Time Frame: Since two weeks after the second dose up 12 month after first dose
|
The incidence of severe cases of COVID-19 and deaths, confirmed through PCR, two weeks after the second vaccination of two vaccination schedules, will be determined.
|
Since two weeks after the second dose up 12 month after first dose
|
Incidence of adverse reactions to the vaccine, local and systemic, solicited and unsolicited, within the period of four weeks after each vaccination of two vaccination schedules, according to the age, adults (18-59 years old) and elder (>60 years)
Time Frame: Four weeks after each dose of vaccine in two vaccination schedules
|
The incidence of adverse reactions to the vaccine, both local and systemic, solicited and unsolicited will be determined.
These adverse reactions will be measured within the period of four weeks after each dose of vaccination of two vaccination schedules.
These adverse reactions will be registered according to the age group in adult (18-59 years old) and elder (60 years of age or older) subjects
|
Four weeks after each dose of vaccine in two vaccination schedules
|
Frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules
Time Frame: Since first dose up to 12 month after
|
The frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules will be determined.
|
Since first dose up to 12 month after
|
Incidence of serious adverse events (SAE) and adverse events in participants who have received at least one dose of the vaccine, in two vaccination schedules
Time Frame: Since first dose up to 12 month after
|
The occurrence of serious adverse events (SAE) and adverse events of special interest in participants who have received at least one dose of the vaccine in two vaccination schedules, will be determined
|
Since first dose up to 12 month after
|
Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, in two vaccination schedules, determined by flow Cytometry and ELISPOT
Time Frame: Since first dose up to 4 weeks after second dose
|
The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, in two vaccination schedules will be evaluated
|
Since first dose up to 4 weeks after second dose
|
Percentage of participants with a significant increase of anti-SARS-CoV-2 antibodies, determined by ELISA
Time Frame: Since first dose up to 2 weeks after second dose
|
The presence of anti-SARS-CoV-2 antibodies in a subgroup of participants, before and two weeks after the administration of each dose of the vaccine, in two vaccination schedules, will be evaluated.
|
Since first dose up to 2 weeks after second dose
|
Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, determined by flow Cytometry and ELISPOT
Time Frame: Since first dose up to 4 weeks after second dose
|
The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, will be evaluated.
|
Since first dose up to 4 weeks after second dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Alexis M Kalergis, PhD, Pontificia Universidad Catolica de Chile
- Study Director: Katia Abarca, MD, Pontificia Universidad Catolica de Chile
- Study Director: Pablo A Gonzalez, PhD, Pontificia Universidad Catolica de Chile
- Study Director: Susan M Bueno, PhD, Pontificia Universidad Catolica de Chile
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Luan N, Li T, Wang Y, Cao H, Yin X, Lin K, Liu C. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Front Immunol. 2022 Apr 8;13:882856. doi: 10.3389/fimmu.2022.882856. eCollection 2022.
- Galvez NMS, Pacheco GA, Schultz BM, Melo-Gonzalez F, Soto JA, Duarte LF, Gonzalez LA, Rivera-Perez D, Rios M, Berrios RV, Vazquez Y, Moreno-Tapia D, Vallejos OP, Andrade CA, Hoppe-Elsholz G, Iturriaga C, Urzua M, Navarrete MS, Rojas A, Fasce R, Fernandez J, Mora J, Ramirez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverria F, Soto-Rifo R, Weiskopf D, Grifoni A, Sette A, Zeng G, Meng W; CoronaVacCL03 Study Group, Gonzalez-Aramundiz JV, Johnson M, Goldblatt D, Gonzalez PA, Abarca K, Bueno SM, Kalergis AM. Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial. Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477.
- Bueno SM, Abarca K, Gonzalez PA, Galvez NM, Soto JA, Duarte LF, Schultz BM, Pacheco GA, Gonzalez LA, Vazquez Y, Rios M, Melo-Gonzalez F, Rivera-Perez D, Iturriaga C, Urzua M, Dominguez A, Andrade CA, Berrios RV, Canedo-Marroquin G, Covian C, Moreno-Tapia D, Saavedra F, Vallejos OP, Donato P, Espinoza P, Fuentes D, Gonzalez M, Guzman P, Munoz-Venturelli P, Perez CM, Potin M, Rojas A, Fasce R, Fernandez J, Mora J, Ramirez E, Gaete-Argel A, Oyarzun-Arrau A, Valiente-Echeverria F, Soto-Rifo R, Weiskopf D, Sette A, Zeng G, Meng W, Gonzalez-Aramundiz JV, Kalergis AM. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv. 2021 Apr 1:2021.03.31.21254494. doi: 10.1101/2021.03.31.21254494. Preprint.
- Duarte LF, Galvez NMS, Iturriaga C, Melo-Gonzalez F, Soto JA, Schultz BM, Urzua M, Gonzalez LA, Vazquez Y, Rios M, Berrios-Rojas RV, Rivera-Perez D, Moreno-Tapia D, Pacheco GA, Vallejos OP, Hoppe-Elsholz G, Navarrete MS, Rojas A, Fasce RA, Fernandez J, Mora J, Ramirez E, Zeng G, Meng W, Gonzalez-Aramundiz JV, Gonzalez PA, Abarca K, Bueno SM, Kalergis AM. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 27, 2020
Primary Completion (Anticipated)
November 10, 2022
Study Completion (Anticipated)
November 10, 2022
Study Registration Dates
First Submitted
November 20, 2020
First Submitted That Met QC Criteria
December 1, 2020
First Posted (Actual)
December 3, 2020
Study Record Updates
Last Update Posted (Actual)
October 24, 2022
Last Update Submitted That Met QC Criteria
October 20, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200708006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on SARS-CoV-2 inactivated vaccine
-
Shanghai Municipal Center for Disease Control and...China National Biotec Group Company LimitedNot yet recruitingMeasles | Rubella | Mumps | Varicella | SARS-CoV-2 InfectionChina
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Sinovac Research and Development Co., Ltd.Recruiting
-
PT Bio FarmaSinovac Life Sciences Co., Ltd.; Faculty of Medicine Universitas Padjadjaran; National Intitute of Health Research and Development, Ministry of Health Republic of IndonesiaCompletedSARS-CoV2 InfectionIndonesia
-
Beijing Minhai Biotechnology Co., LtdShenzhen Kangtai Biological Products Co., LTD; Jiangsu Province Centers for...Unknown
-
Beijing Minhai Biotechnology Co., LtdShenzhen Kangtai Biological Products Co., LTD; Jiangsu Province Centers for...Unknown
-
Laboratorio Elea Phoenix S.A.China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaboratorsCompletedCOVID-19 Virus InfectionArgentina
-
Ruijin HospitalRecruitingCovid19 | SARS-CoV-2 InfectionChina
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.CompletedCOVID-19 | COVID-19 PneumoniaUnited Arab Emirates